Category - Developments

Developments

EyePoint presents YUTIQ 36-month follow up Phase 3 data at ARVO

EyePoint Pharmaceuticals (NASDAQ:EYPT) presented 36-month efficacy and safety data supporting its YUTIQ three-year micro-insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the...

May 1, 2019

Developments

LogicBio’s methylmalonic acidemia candidate gets FDA orphan drug designation

LogicBio Therapeutics’ (NASDAQ:LOGC) investigational pediatric genome editing therapy, LB-001, received FDA orphan drug designation for the treatment of methylmalonic acidemia (MMA). MMA, a rare disease caused by...

April 30, 2019

Developments

AVROBIO’s IND for commercial-scale Fabry disease gene therapy cleared by the FDA

AVROBIO’s (NASDAQ:AVRO) IND for AVR-RD-01 – a gene therapy candidate for the treatment of Fabry disease – has been cleared by the FDA, enabling AVROBIO to use its commercial-scale gene therapy manufacturing system...

April 30, 2019

Developments

Vertex Pharma’s KALYDECO gets FDA approval for use in infants with CF

Vertex Pharma’s (NASDAQ:VRTX) KALYDECO obtained FDA approval for use in infants with cystic fibrosis (CF) between the ages of six and 12 months. KALYDECO is indicated in CF patients who have at least one mutation in the...

April 30, 2019

Developments

MyoKardia’s positive Phase 2 results published in Annals of Internal Medicine

MyoKardia’s (NASDAQ:MYOK) positive Phase 2 trial results of mavacamten for the treatment of obstructive hypertrophic cardiomyopathy (HCM) were recently published in the peer-reviewed journal, Annals of Internal Medicine...

April 30, 2019

Developments

Titan Pharma receives positive EU CHMP opinion for Probuphine (“Sixmo”)

Titan Pharmaceuticals (NASDAQ:TTNP) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for marketing authorization of Sixmo, the brand name for...

April 29, 2019

Developments

Canopy Growth secures site for NY state hemp industrial park

Canopy Growth (TSX:WEED; NYSE:CGC) secured a 308,000-square-foot facility on a 48-acre property in Kirkwood, NY for its hemp industrial park in the southern tier region of New York State. The vision for the property is...

April 29, 2019

Developments

Titan Pharma’s Probuphine implant to treat OUD continues to gain national media attention

Channel 8’s Daytime aired nationally an interview with two senior executives of Titan Pharmaceuticals (NASDAQ:TTNP) – Dane Hallberg, EVP and chief commercial officer, and Dr. Kate DeVarney, EVP and chief scientific...

April 26, 2019

Developments

Orchard Therapeutics doses first patient in cryopreserved gene therapy trial

Orchard Therapeutics (NASDAQ:ORTX) has dosed the first patient in a study evaluating a cryopreserved formulation of OTL-103, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of Wiskott...

April 25, 2019

Developments

Kane Biotech in sales representation pact with SLA Brands

Kane Biotech (TSXV:KNE) entered a strategic partnership with Schiaffino, Lasky, & Associates (SLA Brands) to exclusively represent Kane’s bluestem line of products to distributors and retailers in the U.S. market...

April 24, 2019

Category - Developments

Subscribe